Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18280699 | 0.93 | GAA (0.49) | GAAELANEALDH1A1KDM4ETP53 | |
| SCHEMBL12166081 | 0.89 | KDM4E (0.52) | GAAALDH1A1KDM4ETP53MAPT | |
| SCHEMBL12166069 | 0.82 | MYC (0.45) | GAAELANEALDH1A1KDM4EMAPT | |
| SCHEMBL11926707 | 0.82 | MYC (0.52) | GAAELANEALDH1A1MAPTTSPO | |
| SCHEMBL12166109 | 0.82 | ELANE (0.50) | ELANEALDH1A1KDM4EMAPTTSPO | |
| SCHEMBL18280711 | 0.82 | ALDH1A1 (0.52) | GAAELANEALDH1A1KDM4ETP53 | |
| SCHEMBL18280712 | 0.79 | MYC (0.53) | ALDH1A1KDM4ETP53MAPTRXFP1 | |
| SCHEMBL12166108 | 0.79 | HSD17B10 (0.45) | GAAELANEALDH1A1KDM4ETSPO | |
| SCHEMBL1896211 | 0.79 | HSD17B10 (0.45) | GAAELANEALDH1A1KDM4ETSPO | |
| SCHEMBL31179907 | 0.78 | MYC (0.56) | GAAELANEALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012599-B2 | Nitrogen-containing condensed heterocyclic compounds for OLEDs | MERCK PATENT GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012599-B2 | Nitrogen-containing condensed heterocyclic compounds for OLEDs | MERCK PATENT GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2012-09-13 | — | — | US | disclosed |
| WO-2011060867-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH (DE) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | OCIAD2, OCIAD1, ODC1 | GAA 4431/4885ELANE 1096/4885ALDH1A1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.